Cipla Rises On U.S. FDA Nod For Immunodeficiency Drug

Neal Bhai Reports (NBR) — Cipla Rises On U.S. FDA Nod For Immunodeficiency Drug – Shares of the Mumbai-based drugmaker rose as much as 6.47 percent to Rs 622.75 after U.S. FDA gave its final approval to Efavirenz tablets in strength of 600 mg. Efavirenz Tablets 600 mg is AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s Sustiva which is used in treatment of human immunodeficiency virus type 1 infection, Cipla said in an exchange filing.

Read More →

Donald Trump Misguided Trade War

Trump does dirty business again

Gold Silver Reports (NBR) – Donald Trump Misguided Trade War — U.S. President Donald Trump may sincerely think he’s battling to win Americans a better deal on trade with China. In fact, he’s making a better deal harder to achieve — and threatening to inflict grave economic damage on the U.S. economy in the process.

Read More →